Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In this deeply personal and inspiring conversation, Mike Raab, President & Chief Executive Officer of Ardelyx, and Laura Williams, Chief Patient Officer, share how empathy, resilience, and patient advocacy have shaped both their careers and the culture of the company they’ve built. Mike reflects on an unconventional journey that spans pharmaceutical sales, rare disease leadership at Genzyme, venture capital at NEA, and ultimately leading Ardelyx through some of biotech’s most difficult challenges—including a Complete Response Letter, massive layoffs, and a historic FDA reversal that resulted in approval without additional clinical trials. Laura shares her path from rural Mississippi to becoming a physician, recounting the transformative patient experience during the HIV epidemic that inspired her move from academia into industry and ultimately into a pioneering Chief Patient Officer role. Together, they explore what patient-centricity truly means beyond corporate slogans, how Ardelyx embedded patient advocacy into the C-suite, and why empathy must be a core competency for biotech leadership. The discussion also dives into clinical trial diversity, commercializing therapies for underserved populations, navigating regulatory adversity, responsible capital allocation, and the future of building enduring biotech companies. It is a powerful reminder that when patients become the North Star, resilience, innovation, and impact naturally follow. Biography: Mike Raab Mike has served as Ardelyx’s President and Chief Executive Officer since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA), one of the world’s largest and most successful venture capital firms, where he specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors. Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was senior vice president, therapeutics and general manager of the renal division at Genzyme Corporation, a Sanofi company. In this position, Mike launched and oversaw the sales growth of sevelamer, the leading phosphate binder for the treatment of hyperphosphatemia, with over $1.0 billion in worldwide sales in 2013. Mike was also instrumental in the worldwide launch of Genzyme’s therapies for Gaucher disease, Ceredase and Cerezyme. Laura Williams, MD, MPH Laura has served as Ardelyx’s Chief Patient Officer since 2025, having joined the company in November 2020 as Senior Vice President, Global Therapeutic Strategies and Patient Advocacy. Laura was later promoted to Chief Medical Officer in 2021. Laura is a life science enterprise leader with extensive experience as a pharmaceutical drug developer, healthcare policy advisor, patient advocate, and portfolio strategist. She is an accomplished, results-oriented, physician scientist and board member who is committed to discovering, developing, and commercializing innovative therapies that address unmet medical need. With nearly 30 years of pharmaceutical experience, across all clinical development phases and multiple therapeutic areas, in both large pharma and smaller biotech, Laura has a proven track-record in drug development, as indicated by her leadership and major contributions toward eight drug approvals.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related